Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility
- PMID: 25708048
- PMCID: PMC4331714
- DOI: 10.1186/1471-2164-16-S2-S14
Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility
Figures






References
-
- Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 1999;3(7):564–581. - PubMed
-
- Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N. et al.Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012;55(4):572–581. doi: 10.1093/cid/cis487. - DOI - PMC - PubMed
-
- Dhiman H, Dhanjal JK, Sharma S, Chacko S, Grover S, Grover A. Resisting resistant Mycobacterium tuberculosis naturally: mechanistic insights into the inhibition of the parasite's sole signal peptidase Leader peptidase B. Biochem Biophys Res Commun. 2013;433(4):552–557. doi: 10.1016/j.bbrc.2013.03.013. - DOI - PubMed